Table 1. Description of the EOCs grafted and their engraftment rate.
| Patients | Samples grafted | Take P1 | No Take P1 | Take P1 vs No Take P1 | UA P1 | Take P3 | No Take P3 | Take P3 vs No Take P3 | UA P3 | |
|---|---|---|---|---|---|---|---|---|---|---|
| N | N | N (%) | N (%) | p value | N (%) | N% | p value | |||
| Primary | 55 | 55 | 37 (74%) | 13 (26%) | N.S. | 5 | 28 (60.9%) | 18 (39.1%) | N.S. | 9 |
| Multilocation at first debulking | 10 | 29 | 8 (66.7%) | 4 (33.3%) | 3 | 5 (45.5%) | 6 (54.5%) | 4 | ||
| Recurrence | 5 | 7 | 2 (50%) | 2 (50%) | 3 | 2 (50%) | 2 (50%) | 3 | ||
| serous | 45 | 67 | 38 (67.9%) | 18 (32.1%) | N.S. | 11 | 28 (53.8%) | 24 (46.2%) | N.S. | 15 |
| Mucinous | 2 | 2 | 2 (100%) | 0 | 0 | 1 (50%) | 1 (50%) | 0 | ||
| Clear cell | 2 | 2 | 2 (100%) | 0 | 0 | 1 (100%) | 0 | 1 | ||
| Carcinosarcoma | 4 | 4 | 3 (75%) | 1 (25%) | 0 | 3 (75%) | 1 (25%) | 0 | ||
| endometroid + serous | 1 | 1 | 1 (100%) | 0 | 0 | 1 (100%) | 0 | 0 | ||
| clear cell + serous | 1 | 1 | 1 (100%) | 0 | 0 | 1 (100%) | 0 | 0 | ||
| Grade 1 | 5 | 5 | 3 (60%) | 2 (40%) | N.S. | 0 | 1 (20%) | 4 (80%) | N.S. | 0 |
| Grade 2 | 8 | 10 | 8 (80%) | 2 (20%) | 0 | 8 (80%) | 2 (20%) | 0 | ||
| Grade 3 | 36 | 56 | 31 (68.9%) | 14 (31.1%) | 11 | 23 (56.1%) | 18 (43.9%) | 15 | ||
| Grade ND | 6 | 6 | 5 (83.3%) | 1 (16.7%) | 0 | 3 (60%) | 2 (40%) | 1 | ||
| Stage I | 4 | 4 | 3 (75%) | 1 (25%) | N.S. | 0 | 2 (50%) | 2 (50%) | N.S. | 0 |
| Stage II | 2 | 2 | 0 | 2 (100%) | 0 | 0 | 2 (100%) | 0 | ||
| Stage III | 45 | 67 | 40 (71.4%) | 16 (28.6%) | 11 | 31 (59.6%) | 21 (40.4%) | 15 | ||
| Stage IV | 4 | 4 | 4 (100%) | 0 | 0 | 2 (66.7%) | 1 (33.3%) | 1 | ||
| N- | 14 | 16 | 9 (60%) | 6 (40%) | N.S. | 2 | 5 (35.7%) | 9 (64.3%) | N.S. | 3 |
| N+ | 34 | 52 | 33 (73.3%) | 12 (26.7%) | 9 | 25 (61%) | 16 (39%) | 13 | ||
| median age | 62 | 64 | 61.5 | N.S. | 64 | 64 | 62 | N.S. | 65 | |
| age range | 28-85 | 38-85 | 28-85 | 68-57 | 40.5-85 | 28-85 | 57-72 | |||
| Recurrence in High Grade EOC | ||||||||||
| < 6 months | 5 (100%) | 0 (0%) | 0.008 | 5 (100%) | 0 (0%) | 0.02 | ||||
| 6 to 18 months | 19 (86.4%) | 3 (13.6%) | 15 (68.2%) | 7 (31.8%) | ||||||
| >= 18 months | 8 (47.1%) | 9 (52.9%) | 8 (47.1%) | 9 (52.9%) | ||||||
| Total | 55 | 77 | 47 (71.2%) | 19 (28.8%) | 11 | 35 | 26 (42.6%) | 16 |
EOC tumor samples were stratified according to the principal pathological and clinical characteristics of the disease. Take and No Take designates positive engrafment and tumor growth at passage 1 (P1) and passage 3 (P3) respectively. UA (under assessment) designates tumors grafted on animals and whose status is still pending. Grade ND not determined. Cases included in the recurrence analysis corresponded to clinically documented recurrence before 18 months or cases with no recurrence with a follow up of at least 18 months